As you may have seen, Esperion scientists and collaborators recently published the definitive paper on the mechanism of action for bempedoic acid, “Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis,” in the journal Nature Communications. I sat down with authors and colleagues Narendra Lalwani and Steve Pinkosky to discuss our findings,… Read More
As you know, Esperion is focused on developing and commercializing therapies for the treatment of patients with hypercholesterolemia who are not adequately controlled by currently available lipid-modifying therapies. Like any medical innovation, the journey of bempedoic acid started long before Esperion with the earliest identification of LDL-cholesterol (LDL-C) more than a century ago. So as… Read More
Buongiorno from the ESC Congress! Earlier this week we had the opportunity to attend the 2016 European Society of Cardiology (ESC) Congress in Rome. ESC has become the largest cardiology meeting in the world with more than 32,000 physicians and other healthcare care professionals in attendance this year. This is one of the most important… Read More
American Heart Month is a timely reminder that more still needs to be done for people at risk for cardiovascular disease. As a lipid specialist, patients are frequently referred to me by their primary care physician because they are struggling to manage their patients’ elevated levels of low-density lipoprotein cholesterol (LDL-cholesterol), or “bad” cholesterol. Often… Read More
By now you’ve read the headlines about the high cost of the new cholesterol lowering drugs. We’ve been bombarded with commentary, articles and opinion pieces on these drugs and their high prices. The PCSK9 inhibitors – injectable, biologic drugs that dramatically lower LDL-cholesterol – appear to be very efficacious. But these drugs are priced at… Read More
This brief video blog features April Seiler, Esperion’s Director of Project Management. In this video, April describes how she has experienced the evolution of ETC-1002 and Esperion 2.0, and her insight into the future of Esperion.